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Lynne F Forrest1,2*, Sarah Sowden2, Greg Rubin1,3, Martin White1,2 and Jean Adams1,2Abstract
Background: Early diagnosis and treatment of cancer is thought to be important for improving survival. Longer
time between the onset of cancer symptoms and receipt of treatment may help explain the poorer survival of UK
cancer patients compared to that in other countries.
Socio-economic inequalities in receipt of, and time to, treatment may contribute to socio-economic differences in
cancer survival. Socio-economic inequalities in receipt of lung cancer treatment have been shown in a recent
systematic review. However, no systematic review of the evidence for socio-economic inequalities in time to
presentation (patient interval), time to first investigation (primary care interval), time to secondary care investigation
(referral interval), time to diagnosis (diagnostic interval), and time to treatment (treatment interval) has been
conducted.
This review aims to assess the published and grey literature evidence for socio-economic inequalities in the length
of time spent on the lung cancer diagnostic and treatment pathway, examining interim intervals on the pathway
where inequalities might occur.
Methods: Systematic methods will be used to identify relevant studies, assess study eligibility for inclusion, and
evaluate study quality. The online databases of MEDLINE, EMBASE, and CINAHL will be searched to locate cohort
studies of adults with a primary diagnosis of lung cancer; where the outcome is mean or median time to the
interval endpoint (or a suitable proxy measure of this), or the likelihood of longer or shorter time to the endpoint;
analysed by a measure of socio-economic position. Meta-analysis will be conducted if there are sufficient studies
available with suitable data.
Discussion: This review will systematically determine if there are socio-economic inequalities in time from symptom
onset to treatment for lung cancer. If such inequalities are present, our review evidence will help inform the
development of interventions to reduce the time to diagnosis and treatment, ultimately helping to reduce
socio-economic inequalities in survival.
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Lung cancer is the most common cancer worldwide. In
the USA and the UK it is the second most incident can-
cer [1,2], as well as the most common cause of cancer
mortality [2,3]. In the UK, fewer than 10% of those diag-
nosed with lung cancer survive for 5 years [4]. Longer
time between the onset of cancer symptoms and receipt
of treatment may contribute to the poorer survival of
UK cancer patients compared to that found in other
countries [5]. An early model of cancer delay, the Ander-
son model, attributed the majority of delays to patient
factors but this has been updated to consider patient,
tumour, and healthcare system factors (Figure 1) [6].
The following intervals on the care pathway have been
identified: patient (incorporating appraisal and help-
seeking intervals), primary care, referral, diagnostic, and
treatment intervals [7-9], illustrated by a pathway model
(Figure 2) [10]. Early diagnosis of cancer is thought to be
important for improving outcomes, as survival is better
for patients who are diagnosed at an early stage since
they are more likely to be suitable for receipt of poten-
tially curative treatment [5].
In 2000, the UK NHS Cancer Plan pledged to reduce
delay in diagnosis and treatment and increase survival
whilst acting to reduce inequalities [11]. In England, the
National Awareness and Early Diagnosis Initiative is a
scheme designed to encourage early presentation of pa-
tients to primary care and to improve general practi-
tioner (GP) cancer recognition and referral. It proposes
that delays may lead to diagnosis at a later disease stage
and thus result in ‘potentially-avoidable’ deaths [5].
Intervention-generated inequalities are health inequal-
ities that result from the way that health interventions
are organised and delivered [12], so that although overallFigure 1 Refined Anderson model of total patient delay [6].health may improve as the result of an intervention, dif-
ferences in access to the intervention, differential uptake
and delays in uptake might result in inequalities in out-
come. Inequalities are likely to occur at many different
stages of intervention pathways and act in a cumulative
way [12].
A socio-economic gradient for lung cancer survival [13]
is found in the UK. Socio-economic inequalities in receipt
of lung cancer treatment have been shown in a recent sys-
tematic review and meta-analysis [14] and there is some
evidence that inequalities in treatment contribute to
socio-economic inequalities in survival [15]. It has also
been suggested that inequalities in time to diagnosis and
treatment might contribute to socio-economic differences
in cancer survival [5]. However, there has been no system-
atic review of the evidence for socio-economic inequalities
in time from onset of first symptom to treatment, and
in the interim patient, primary care, referral, diagnostic,
and treatment intervals on the lung cancer care pathway
where inequalities might occur.
This review aims to investigate whether there are socio-
economic inequalities in the length of time spent on the
lung cancer diagnostic and treatment pathway and, if so,
in which intervals (patient, primary care, referral, diagnos-
tic, treatment) inequalities occur.
Methods/design
Poorly defined definitions of the important time points
that characterise pathway intervals have meant that it has
previously been difficult to compare studies. An inter-
national consensus working group recently identified the
following four time points as important: date of first
symptom, date of first presentation, date of referral to sec-
ondary care, and date of diagnosis [7]. These can be used
Figure 2 Intervals on the cancer diagnosis and treatment pathway [10].
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the Anderson (Figure 1) [6] and Hansen (Figure 2) [10]
models of delay.
The following time intervals will be investigated: patient
interval (time from the interval start point defined as date
of first symptom, to the interval end point defined as date
of first presentation); primary care interval (time from
date of first presentation to date of first investigation); re-
ferral interval (time from date of GP referral to secondary
care investigation); diagnostic interval (time from date of
secondary care investigation to diagnosis OR time from
GP referral to diagnosis); and treatment interval (time
from diagnosis to treatment OR time from GP referral to
treatment).
Search strategy
Systematic methods will be used to identify relevant
studies, assess study eligibility for inclusion, and evaluate
study quality. A search will be undertaken to locate all
studies published up to the date that the search is run,
with a title and abstract published in English, examining
differences, by socio-economic position (SEP), in patient,
primary care, referral, diagnostic, and treatment time in-
tervals on the care pathway for lung cancer. The
searches will be re-run just before the final analyses and
any further studies retrieved for inclusion.
One researcher (LF) will develop the search strategy,
which will then be refined with the help of an Informa-
tion Scientist and used to search the online databases of
MEDLINE, EMBASE, and CINAHL. The search terms
will be adapted for the different databases. Additional
studies will be identified by reviewing the reference lists
of relevant studies identified from the search and by
using a forward citation search to identify more recent
studies that have cited an older, relevant study. Grey lit-
erature including reports from cancer registries, lung
cancer audit reports, published abstracts, and theses willalso be searched for. EndNote software will be used to
manage the references.
Study eligibility
The following types of study will be eligible for
inclusion:
 Cohort studies of adult participants who have a
primary diagnosis of lung cancer (small-cell lung
cancer or non-small-cell lung cancer – ICD10 C33
C34); published in a peer-reviewed journal or in the
grey literature up to the date that the search is run;
where the outcome is:○ Mean or median time (days) to the interval
endpoint (or a suitable proxy measure of this);
○ OR the likelihood (odds ratio or hazard ratio with
95% confidence intervals) of longer or shorter
time to the endpoint;
○ AND where outcome is analysed by a measure of
SEP (such as an individual or area-based measure
of deprivation, poverty, income, or education).
The following are considered suitable proxy measures
of length of time intervals on the pathway:
 Stage at diagnosis or stage at start of treatment [16]
 Type of referral (urgent vs. routine) [17]
 Emergency presentation [18]
 Number of pre-referral consultations [19]
The searches will be re-run just before the final analyses
and any further studies retrieved for inclusion.
Preliminary independent screening of the titles and ab-
stracts obtained from the database searches will be car-
ried out by two researchers (LF and SS). Initial screening
of titles will be carried out to remove obviously irrelevant
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LF, the early pilot searches recovered studies that, al-
though they conducted analyses by SEP, did not always
mention this in the abstract or title. Therefore, in the title
search, any titles that refer to delay in, or time intervals
for, lung cancer will be retained. Titles that consider
disparities in cancer treatment will also be included as
further checking of the abstract is required to see if in-
equalities in intervals on the care pathway to treatment
are also examined.
Selected abstracts will then be screened and a subset
of studies will be selected for further review and the full
article obtained. Abstracts that refer to socio-economic
inequalities in time intervals on the care pathway will be
retained. Abstracts that refer to racial, ethnic, geograph-
ical, sex, and age-related time disparities as well as dis-
parities by insurance type will also be retained as often
these papers also look at SEP, even if this is not men-
tioned in the abstract. Two researchers (LF and SS) will
then independently assess the selected full papers for eli-
gibility according to the study-eligibility criteria detailed
above. Any disagreements at any of the screening stages
will be resolved by discussion between the two reviewers
in the first instance. If agreement cannot be reached,
then a third reviewer (JA) will independently review the
title, abstract or full paper, as appropriate, and a majority
decision will be taken on inclusion/exclusion.
Data extraction
Data extraction will be carried out by LF and checked by
SS using a pro-forma to be developed by LF for this pur-
pose, based on previous review work [14]. Data relating to
study authors, journal, study design, year of study, data
source, population included, number of participants, years
of diagnosis, time interval examined, measure of SEP, con-
founding variables included in the analysis (such as age,
sex, stage, histology, histological subtype, co-morbidity,
performance status, marital status, smoking status, cancer
network, health board, hospital, distance from hospital or
travel time, ethnicity, insurance status), outcome measures
(mean or median time interval [or the proxy measure of
time used]; odds ratio, hazard ratio), statistical tests car-
ried out, significance (P values), precision (confidence in-
tervals), and other variables that were significant, will be
recorded.
There is evidence to suggest that insurance status is an
important factor relating to access to lung cancer care in
the US healthcare system [20] and so may impact on
time-intervals on the care pathway. Therefore, as in a
previous systematic review of intervention-generated in-
equalities [14], studies will be split into three categories:
those carried out in a healthcare system free at the point
of access (similar to the UK); those based on an insur-
ance system (similar to the USA); those that include amixture of free care and social insurance-based payment
(some European systems).
Study quality
Study quality will be appraised using a quality checklist
based on that developed for a previous systematic review
[14] and on the ‘Aarhus checklist’ [7], which has been
developed to help assess the quality of studies that measure
intervals on the cancer diagnostic and treatment pathway.
The following criteria will be used to assess study qual-
ity: study design, size, setting, dates, data sources, eligibil-
ity criteria, type of population included (including number
of participants potentially eligible, number actually in-
cluded, number analysed), missing or incomplete data re-
ported, variables included (in terms of outcome, exposure,
predictors, confounders), validity of the definition of time
points and intervals, validity of the measure used to esti-
mate time interval, validity of the measure of SEP, type of
statistical analysis carried out, unadjusted and adjusted es-
timates reported, precision (confidence intervals), signifi-
cance (P values) given, limitations of the study, potential
bias addressed, and external validity of results.
Statistical analysis
Random effects meta-analysis will be considered if there
are sufficient studies which have the same type of out-
come measure using the same comparator, across the
same time interval. The I2 statistic will be used to assess
heterogeneity. If it is not possible to conduct a meta-
analysis, due to the heterogeneity of the studies, then
narrative analysis will be carried out and the use of Har-
vest Plot methodology will be considered [21]. This is a
method that has been devised for synthesising evidence
from studies looking at the differential effects of inter-
ventions, where meta-analysis is not suitable.
Planned sub-group analyses by interval (patient, pri-
mary care, referral, diagnostic, and treatment intervals)
and, within these intervals, by healthcare system cat-
egory will be conducted. Studies reporting a proxy time
interval measure will be analysed separately. Sensitivity
analyses will be undertaken where required, for example,
to examine the effect of including all potentially-eligible
studies or only high quality studies in meta-analyses, or
looking at both published and grey literature results
compared to only those from published papers.
Discussion
This review will systematically determine if there are
socio-economic inequalities in time from symptom onset
to treatment for lung cancer. If such inequalities are
present, our review evidence will help inform the develop-
ment of interventions to reduce the time to diagnosis and
treatment, ultimately helping to reduce socio-economic
inequalities in survival.
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